Literature DB >> 27173366

Antiangiogenic Effect of Bevacizumab: Application of Arterial Spin-Labeling Perfusion MR Imaging in a Rat Glioblastoma Model.

T J Yun1, H R Cho1, S H Choi2, H Kim1, J-K Won3, S-W Park4, J-H Kim1, C-H Sohn1, M H Han5.   

Abstract

BACKGROUND AND
PURPOSE: The usefulness of arterial spin-labeling for the evaluation of the effect of the antiangiogenic therapy has not been elucidated. Our aim was to evaluate the antiangiogenic effect of bevacizumab in a rat glioblastoma model based on arterial spin-labeling perfusion MR imaging.
MATERIALS AND METHODS: DSC and arterial spin-labeling perfusion MR imaging were performed by using a 9.4T MR imaging scanner in nude rats with glioblastoma. Rats were randomly assigned to the following 3 groups: control, 3-day treatment, and 10-day treatment after bevacizumab injection. One-way analysis of variance with a post hoc test was used to compare perfusion parameters (eg, normalized CBV and normalized CBF from DSC MR imaging and normalized CBF based on arterial spin-labeling) with microvessel area on histology. The Pearson correlations between perfusion parameters and microvessel area were also determined.
RESULTS: All of the normalized CBV from DSC, normalized CBF from DSC, normalized CBF from arterial spin-labeling, and microvessel area values showed significant decrease after treatment (P < .001, P < .001, P = .005, and P < .001, respectively). In addition, normalized CBV and normalized CBF from DSC and normalized CBF from arterial spin-labeling strongly correlated with microvessel area (correlation coefficient, r = 0.911, 0.869, and 0.860, respectively; P < .001 for all).
CONCLUSIONS: Normalized CBF based on arterial spin-labeling and normalized CBV and normalized CBF based on DSC have the potential for evaluating the effect of antiangiogenic therapy on glioblastomas treated with bevacizumab, with a strong correlation with microvessel area.
© 2016 by American Journal of Neuroradiology.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27173366      PMCID: PMC7984714          DOI: 10.3174/ajnr.A4800

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  25 in total

1.  Understanding and optimizing the amplitude modulated control for multiple-slice continuous arterial spin labeling.

Authors:  Jane F Utting; David L Thomas; David G Gadian; Robert W Helliar; Mark F Lythgoe; Roger J Ordidge
Journal:  Magn Reson Med       Date:  2005-09       Impact factor: 4.668

2.  Early evaluation of tumoral response to antiangiogenic therapy by arterial spin labeling perfusion magnetic resonance imaging and susceptibility weighted imaging in a patient with recurrent glioblastoma receiving bevacizumab.

Authors:  Slim Fellah; Nadine Girard; Olivier Chinot; Patrick J Cozzone; Virginie Callot
Journal:  J Clin Oncol       Date:  2011-01-24       Impact factor: 44.544

3.  Classification of tumor area using combined DCE and DSC MRI in patients with glioblastoma.

Authors:  Moran Artzi; Deborah T Blumenthal; Felix Bokstein; Guy Nadav; Gilad Liberman; Orna Aizenstein; Dafna Ben Bashat
Journal:  J Neurooncol       Date:  2014-11-05       Impact factor: 4.130

4.  Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma.

Authors:  Olivier Keunen; Mikael Johansson; Anaïs Oudin; Morgane Sanzey; Siti A Abdul Rahim; Fred Fack; Frits Thorsen; Torfinn Taxt; Michal Bartos; Radovan Jirik; Hrvoje Miletic; Jian Wang; Daniel Stieber; Linda Stuhr; Ingrid Moen; Cecilie Brekke Rygh; Rolf Bjerkvig; Simone P Niclou
Journal:  Proc Natl Acad Sci U S A       Date:  2011-02-14       Impact factor: 11.205

5.  Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma.

Authors:  James J Vredenburgh; Annick Desjardins; James E Herndon; Jeannette M Dowell; David A Reardon; Jennifer A Quinn; Jeremy N Rich; Sith Sathornsumetee; Sridharan Gururangan; Melissa Wagner; Darell D Bigner; Allan H Friedman; Henry S Friedman
Journal:  Clin Cancer Res       Date:  2007-02-15       Impact factor: 12.531

6.  MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab.

Authors:  Robert J Harris; Timothy F Cloughesy; Anthony J Hardy; Linda M Liau; Whitney B Pope; Phioanh L Nghiemphu; Albert Lai; Benjamin M Ellingson
Journal:  J Neurooncol       Date:  2015-03-15       Impact factor: 4.130

Review 7.  Perfusion MRI: the five most frequently asked technical questions.

Authors:  Marco Essig; Mark S Shiroishi; Thanh Binh Nguyen; Marc Saake; James M Provenzale; David Enterline; Nicoletta Anzalone; Arnd Dörfler; Alex Rovira; Max Wintermark; Meng Law
Journal:  AJR Am J Roentgenol       Date:  2013-01       Impact factor: 3.959

8.  Perfusion imaging.

Authors:  J A Detre; J S Leigh; D S Williams; A P Koretsky
Journal:  Magn Reson Med       Date:  1992-01       Impact factor: 4.668

Review 9.  Angiogenesis in brain tumours.

Authors:  Rakesh K Jain; Emmanuelle di Tomaso; Dan G Duda; Jay S Loeffler; A Gregory Sorensen; Tracy T Batchelor
Journal:  Nat Rev Neurosci       Date:  2007-08       Impact factor: 34.870

10.  Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma.

Authors:  Henry S Friedman; Michael D Prados; Patrick Y Wen; Tom Mikkelsen; David Schiff; Lauren E Abrey; W K Alfred Yung; Nina Paleologos; Martin K Nicholas; Randy Jensen; James Vredenburgh; Jane Huang; Maoxia Zheng; Timothy Cloughesy
Journal:  J Clin Oncol       Date:  2009-08-31       Impact factor: 44.544

View more
  5 in total

Review 1.  Perfusion MRI in treatment evaluation of glioblastomas: Clinical relevance of current and future techniques.

Authors:  Bart R J van Dijken; Peter Jan van Laar; Marion Smits; Jan Willem Dankbaar; Roelien H Enting; Anouk van der Hoorn
Journal:  J Magn Reson Imaging       Date:  2019-01       Impact factor: 4.813

Review 2.  Imaging-guided precision medicine in glioblastoma patients treated with immune checkpoint modulators: research trend and future directions in the field of imaging biomarkers and artificial intelligence.

Authors:  Mathieu Sinigaglia; Tarek Assi; Florent L Besson; Samy Ammari; Myriam Edjlali; Whitney Feltus; Laura Rozenblum-Beddok; Binsheng Zhao; Lawrence H Schwartz; Fatima-Zohra Mokrane; Laurent Dercle
Journal:  EJNMMI Res       Date:  2019-08-20       Impact factor: 3.138

3.  Increased Antiangiogenic Effect by Blocking CCL2-dependent Macrophages in a Rodent Glioblastoma Model: Correlation Study with Dynamic Susceptibility Contrast Perfusion MRI.

Authors:  Hye Rim Cho; Nisha Kumari; Hien Thi Vu; Hyeonjin Kim; Chul-Kee Park; Seung Hong Choi
Journal:  Sci Rep       Date:  2019-07-31       Impact factor: 4.379

4.  Development and characterization of sorafenib-loaded lipid nanocapsules for the treatment of glioblastoma.

Authors:  Anne Clavreul; Emilie Roger; Milad Pourbaghi-Masouleh; Laurent Lemaire; Clément Tétaud; Philippe Menei
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

5.  Cerebral and tumoral blood flow in adult gliomas: a systematic review of results from magnetic resonance imaging.

Authors:  Mueez Waqar; Daniel Lewis; Erjon Agushi; Matthew Gittins; Alan Jackson; David Coope
Journal:  Br J Radiol       Date:  2021-06-09       Impact factor: 3.629

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.